Journals / Türk Nefroloji Diyaliz ve Transplantasyon Dergisi / 2018 / Cilt: 27 - Sayı: 2

Significance of Apelin-13 for Inflammation and Cardiac Morphology in Peritoneal Dialysis Patients

Periton Diyaliz Hastalarında Serum Apelin-13’ün İnflamasyon ve Kardiyak Morfoloji İçin Önemi

Pages
150–156
Publication Date
2022-11-05
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

CRP, NLR, CIMT were significantly higher in patients than controls(p

📌 3 Key Takeaways

🎯
Objective & Hypothesis:OBJECTIVE: Apelin-13 is a biomarker that was shown to be related to cardiovascular disease risk inperitoneal dialysis patients.
📊
Key Findings & Data:The aim of our study was to investigate the association of serum apelin-13levels with inflammation, carotid artery intima media thickness (CIMT) and echocardiographicparameters in peritoneal dialysis patients.MATERIAL and METHODS: 33 patient receiving peritoneal dialysis treatment (15 female) and 27healthy controls (11 female) were enrolled.
💡
Conclusion & Impact:CRP, NLR, CIMT were significantly higher in patients than controls(p
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

OBJECTIVE: Apelin-13 is a biomarker that was shown to be related to cardiovascular disease risk inperitoneal dialysis patients. The aim of our study was to investigate the association of serum apelin-13levels with inflammation, carotid artery intima media thickness (CIMT) and echocardiographicparameters in peritoneal dialysis patients.MATERIAL and METHODS: 33 patient receiving peritoneal dialysis treatment (15 female) and 27healthy controls (11 female) were enrolled. CIMT and echocardiographic measurements of all patientsand controls were taken. Serum apelin-13 levels were measured by ELISA. Apelin-13, c-reactiveprotein (CRP), neutrophil-to-lymphocyte ratio (NLR), echocardiographic parameters and CIMT valueswere compared between patients and controls.RESULTS: Apelin-13 was lower in the patient group [58 (12-131) ng/L] than in the control group[76 (18-130) ng/L] (p=0.083). CRP, NLR, CIMT were significantly higher in patients than controls(p

Özet

AMAÇ: Apelin-13, periton diyalizi hastalarında tanımlanmış kardiyovasküler hastalık riski ile ilişkili bir belirteçtir. Çalışmanın amacı periton diyalizi hastalarında serum apelin-13 düzeyleri ile inflamasyon, karotis arter intima-media kalınlığı (KİMK) ve ekokardiyografik parametreler arasındaki ilişkiyi araştırmaktır. GEREÇ ve YÖNTEMLER: Çalışmaya 33 periton diyaliz tedavisi alan hasta (15’i kadın) ile 27 sağlıklı (11’i kadın) kontrol alındı. Hasta ve kontrol grubunun tümünün KİMK ve ekokardiyografik ölçümleri alındı. Serum apelin ölçümleri ELISA yöntemi ile çalışıldı. Gruplar arasında apelin-13, c-reaktif protein (CRP), nötrofil/lenfosit oranı (NLO), ekokardiyografik bulgular ve KİMK değerleri karşılaştırıldı. BULGULAR: Apelin-13 hasta grubunda kontrol grubuna göre daha düşük saptandı. [58 ng/L (12- 131)]’a karşın 76 ng/L [(18-130), p=0,083]. Hasta grubunda kontrol grubuna göre CRP, NLO, KİMK anlamlı olarak daha yüksekti (p

🔖

Cite This Article

KAYADİBİ, H., ESER, B., KAHVECİOĞLU, S., YAYAR, Ö., KURTOĞLU, Ü., KARAGÖZ, İ. S., ÖZMEN, S. Ü., DOĞAN, T., DOĞAN, İ. (2022). Significance of Apelin-13 for Inflammation and Cardiac Morphology in Peritoneal Dialysis Patients. Türk Nefroloji Diyaliz ve Transplantasyon Dergisi, Cilt: 27 - Sayı: 2, 150–156. https://ajindex.com/articles/636031

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (2)

  1. United States Renal Data System, Atlas of end-stage renal disease in United States, USRDS 2006
  2. Annual Data Report, National Institute of Diabetes and digestive and Kidney Diseases, Bethesda, Md, USA, Washington:Minneapolis Medical Research Foundation, 2006 2. Walatek B, Sułowicz W: Cardiorenal syndrome-alternate challenge for nephrologist. Przegl Lek 2011;68:619-628 3. Collins AJ: Cardiovascular mortality in end-stage renal disease. Am J Med Sci 2003;325:163-167 4. Jansen MA, Termorshuizen F, Korevaar JC, Dekker FW, Boeschoten E, Krediet RT; NECOSAD Study Group: Predictors of survival in anuric peritoneal dialysis patients. Kidney Int 2005;68:1199-1205 5. Ahima RS: Metabolic actions of adipocyte hormones: Focus on adiponectin. Obesity (Silver Spring) 2006;14 Suppl 1:9S-15S 6. Beltowski J: Apelin and visfatin: Unique “beneficial” adipokines upregulated in obesity. Med Sci Monit 2006;12:112-119 7. Ladeiras-Lopes R, Ferreira-Martins J, Leite-Moreira AF: The apelinergic system: The role played in human physiology and pathology and potential therapeutic applications. Arq Bras Cardiol 2008;90:343-349 8. Rastaldo R, Cappello S, Folino A, Losano G: Effect of apelinapelin receptor system in postischaemic myocardial protection: A pharmacological postconditioning tool? Antioxid Redox Signal 2011;14:909-922 9. Foldes G, Harkay F, Szokodi I: Circulating and cardiac levels of apelin, the novel ligand of the orphan receptor APJ, in patients with heart failure. Biochem Biophys Res Commun 2003;308:480-485 10. Przewlocka-Kosmala M, Kotwica T, Mysiak A, Kosmala W: Reduced circulating apelin in essential hypertension and its association with cardiac dysfunction. J Hypertens 2011;29:971-979 11. Codognotto M, Piccoli A, Zaninotto M, Mion M, Vertolli U, Tona F, Boffa GM: Evidence of decreased circulating apelin beyond heart involvement in uremic cardiomyopathy. Am J Nephrol 2007;27:1-6 12. El-Shehaby AM, El-Khatib MM, Battah AA, Roshdy AR: Apelin: A potential link between inflammation and cardiovascular disease in end stage renal disease patients. Scand J Clin Lab Invest 2010;70:421-427 13. Sahn DJ, De Maria A, Kisslo J, Weyman A: Recommendations regarding quantitation in M-mode echocardiography: Results of a survey of echocardiographic measurements. Circulation 1978;58:1072-1083 14. Zoccali C, Mallamaci F, Tripepi G: Inflammatory proteins as predictors of cardiovascular disease in patients with end-stage renal disease. Nephrol Dial Transplant 2004;19:67-72 15. Zhang X, Ye Q,